Physician profile
Thomas Bresley
NPI 1124210133
$3,567.44
in general payments reported to CMS, 2019-2025
27 companies · $78.77 in 2025
The $78.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $324 · 2021: $737 · 2022: $603 · 2023: $774 · 2024: $520 · 2025: $78.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $832.92 | 2019-2024 | Belbuca, Belbuca, Xtampza |
| Abbott Laboratories | $616.04 | 2021-2025 | Proclaim, Octrode, Eterna |
| Scilex Pharmaceuticals INC. | $402.20 | 2019-2024 | Ztlido |
| Arbor Pharmaceuticals, INC. | $219.05 | 2019-2021 | |
| Boston Scientific Corporation | $196.04 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.47 | 2019-2023 | Relistor |
| Forte Bio-Pharma LLC | $142.62 | 2019-2024 | Prolate, Nalocet |
| Abbvie INC. | $122.10 | 2021-2025 | Ubrelvy, Qulipta |
| Grt US Holding, INC. | $102.51 | 2021-2022 | |
| Pfizer INC. | $80.01 | 2019-2020 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Valinor Pharma, LLC | $69.07 | 2023-2024 | Movantik |
| Hikma Pharmaceuticals USA | $65.64 | 2021-2024 | Kloxxado |
| Mdd US Operations, LLC | $60.40 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $59.29 | 2023-2024 | Levorphanol Tartrate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $54.92 | 2019 | |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Kaleo, INC. | $36.64 | 2019 | |
| Si-Bone, INC. | $30.46 | 2022 | |
| Protega Pharmaceutials INC | $20.05 | 2023 | Roxybond |
| Fidia Pharma USA INC. | $18.78 | 2019 | |
| Almatica Pharma LLC | $18.19 | 2021 | |
| Masimo Corporation | $18.02 | 2023 | Patient Safetynet System |
| Biodelivery Sciences International, INC. | $16.47 | 2019 | |
| Shionogi INC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bresley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.